|
DEVELOPMENT AND EFFECTIVENESS STUDY OF PREVENTABLE SYSTEM FOR DRUG INDUCED ADVERSE DRUG EVENTS IN PATIENTS RECEIVING ANTIRETROVIRAL MEDICINE AT DAYCARE CLINIC, NAN HOSPITAL |
|---|---|
| รหัสดีโอไอ | |
| Creator | Sutthigan Kiattiyot |
| Title | DEVELOPMENT AND EFFECTIVENESS STUDY OF PREVENTABLE SYSTEM FOR DRUG INDUCED ADVERSE DRUG EVENTS IN PATIENTS RECEIVING ANTIRETROVIRAL MEDICINE AT DAYCARE CLINIC, NAN HOSPITAL |
| Contributor | Nantawarn Kitikannakorn |
| Publisher | Faculty of pharmacy, Silpakorn University |
| Publication Year | 2564 |
| Journal Title | Thai Bulletin of Pharmaceutical Sciences |
| Journal Vol. | 16 |
| Journal No. | 2(July-December)2021 |
| Page no. | 1-15 |
| Keyword | drug interaction, anti-retroviral agents, adverse drug events |
| URL Website | https://li01.tci-thaijo.org/index.php/TBPS |
| ISSN | 2586-8659 |
| Abstract | This study utilized mixed methods research which was divided into 3 phases. The first phase was a cross-sectional descriptive study primarily aimed to examine the prevalence of drug interaction in patients receiving antiretroviral agents. The second phase was an action research study with the purpose to develop a system in preventing adverse events from these interactions of patients taking antiretroviral agents. Lastly, another cross-sectional descriptive study was applied to assess the effects of the prevention system of adverse drug events from the drug interaction of patients receiving antiretroviral agents. The results from Phase 1 revealed that the prevalence of drug interaction in patients receiving anti-retroviral agents between May 2018 and January 2019 garnered thirty percent (30%). The analysis of data for Phase 2 applied the principles of the Pareto diagram. The focus group included seven (7) medical personnel and two (2) leaders of infected people in the Nan Province. It further revealed that the group discussion team jointly developed a follow-up system for patients receiving efavirenz-amlodipine and efavirenz-simvastatin for the first time. Furthermore, it set the tracking period to be less than 1 month and established a system to prevent the use of NSAIDs in patients taking tenofovir called |
